Scott Rothbort, "The Finance Professor", has moved the LakeView Asset Management Blog to the all new TheFinanceProfessor.com website.
TheFinanceProfessor.com is a unique and dynamic educational social networking site. So join us as we all Express Our Knowledge.
--- Exchange information and ideas in the Study Hall Forum
--- Interact with other members in our real time chat in The Trading Room
--- Help to build our Finance Wiki
--- Use the online Financial Calculator
--- Participate in an Investment Club.Join an existing club or start your won. If you are unaffiliated then The Finance Professor welcomes you to his own club
--- Upload your resume for thousands of potential employers to search
--- Read what The Finance Professor, Scott Rothbort has to say in his exclusive blog
--- Express Your Knowledge by submitting your own article for publication in the Call For Papers section
--- Subscribe to a newsletter written by one of many Wall Street professionals
Wednesday, April 16, 2008
Tuesday, April 01, 2008
Amylin Stock Is Catching A Bid
Amylin Pharmaceuticals (AMLN) has really been on a tear these past two trading days. As a long term holder of AMLN this is a pleasant development. However, I have to ask why the sudden jump in the stock over the past two trading sessions? There are several reasons for the sudden rise of AMLN of which any one or a combination of could be causing the rise. Here are some of those causal factors:
• The stock was simply too oversold and short interest climbed too high
• With all of the negative news about Zetia from Schering Plough (SGP) and Lipitor from Pfizer (PFE) and other statins perhaps someone finally woke up to the fact that diabetes treatment is all that much more important and the big cap pharmaceutical companies may be forced to buy AMLN
• The decline of the inhaled insulin product lines gives AMLN approved and commercially available products – Byetta and Symlin - more credibility and sales potential.
I continue to believe that AMLN Byetta LAR long acting formulation will be approved and once that occurs we will see a huge jump in analysts estimates and future sales. That is at least a year out but well worth the wait as Byetta and Symlin sales continue to grow.
At the time of this Blog entry Scott Rothbort, his family and or clients of LakeView Asset Management, LLC were long shares of AMLN --- although positions can change at any time.
• The stock was simply too oversold and short interest climbed too high
• With all of the negative news about Zetia from Schering Plough (SGP) and Lipitor from Pfizer (PFE) and other statins perhaps someone finally woke up to the fact that diabetes treatment is all that much more important and the big cap pharmaceutical companies may be forced to buy AMLN
• The decline of the inhaled insulin product lines gives AMLN approved and commercially available products – Byetta and Symlin - more credibility and sales potential.
I continue to believe that AMLN Byetta LAR long acting formulation will be approved and once that occurs we will see a huge jump in analysts estimates and future sales. That is at least a year out but well worth the wait as Byetta and Symlin sales continue to grow.
At the time of this Blog entry Scott Rothbort, his family and or clients of LakeView Asset Management, LLC were long shares of AMLN --- although positions can change at any time.
Subscribe to:
Posts (Atom)
